Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020

Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Doxil/Caelyx sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

• Therapy area profile including patient population for the US, EU and Japan (seven major markets)
• Analysis and review of Doxil/Caelyx including sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Doxil/Caelyx including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales estimates for 2002-2020 for Doxil/Caelyx in the seven major markets

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Ovarian Cancer
2.2 Ovarian Cancer Market
2.3 Epidemiology
2.4 Etiology
  2.4.1 Age
  2.4.2 Inherited Gene Mutations
  2.4.3 A Previous Cancer Diagnosis
  2.4.4 Early Menstruation or Late menopause
  2.4.5 Family History of Ovarian Cancer
2.5 GlobalData Market Forecasts Report Guidance

3 OVARIAN CANCER: MARKET CHARACTERIZATION

3.1 Ovarian Cancer Market
3.2 Ovarian Cancer Market Forecasts and CAGR
3.3 Drivers for Ovarian Cancer Market
  3.3.1 High Incidence
  3.3.2 High Mortality Rate
  3.3.3 Increased Use of Chemotherapy in Ovarian Cancer
  3.3.4 Emergence of Targeted Therapy Drugs
  3.3.5 Recurrence of Tumor
  3.3.6 Low Initial Diagnosis Rate

4 TUMOR-NODE-METASTASES (TNM) CLASSIFICATION OF OVARIAN CANCER

5 DOXIL

5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Study
5.4 Approval History of Doxil
5.5 Factors Affecting Sales of Doxil
  5.5.1 Supply Constraint
  5.5.2 Generics Unavailability
  5.5.3 Strong Pipeline
5.6 Drug Evaluation
  5.6.1 Drug Risk Benefit Score
  5.6.2 Intensity of Competition
5.7 Sales Forecasts
  5.7.1 Target Patient Pool of Doxil
  5.7.2 Dosing
  5.7.3 Market Penetration
  5.7.4 Annual Cost of Therapy
  5.7.5 Sales Projections of Doxil

6 OVARIAN CANCER MARKET: APPENDIX

6.1 Market Definitions
6.2 Abberiviations
6.3 Research Methodology
  6.3.1 Coverage
  6.3.2 Secondary Research
  6.3.3 Forecasting
  6.3.4 Number of Patients Approved to Take the Drug
  6.3.5 Net Penetration of Drug
  6.3.6 Net Annual Dosing
  6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources

LIST OF TABLES

Table 1: Ovarian Cancer, Incidences and Mortality, 2008–2030
Table 2: Detailed TNM Classification
Table 3: Study Details
Table 4: Approval of Doxil
Table 5: Drug Risk Benefit Score
Table 6: Doxil, Ovarian Cancer, Global, Annual Cost of Therapy ($), 2011
Table 7: Doxil, Ovarian Cancer, Global, Sales Estimates ($m), 2002-2020
Table 8: Doxil, Ovarian Cancer, The US, Sales Estimates ($m), 2002-2020
Table 9: Doxil, Ovarian Cancer, The UK, Sales Estimates ($m), 2002-2020
Table 10: Doxil, Ovarian Cancer, France, Sales Estimates ($m), 2002-2020
Table 11: Doxil, Ovarian Cancer, Germany, Sales Estimates ($m), 2002-2020
Table 12: Doxil, Ovarian Cancer, Italy, Sales Estimates ($m), 2002-2020
Table 13: Doxil, Ovarian Cancer, Spain, Sales Estimates ($m), 2002-2020
Table 14: Doxil , Ovarian Cancer, Japan, Sales Estimates ($m), 2009-2020

LIST OF FIGURES




1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030
Figure 4: Oncology, Worldwide, Incidence (million), 2008-2030
Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030
Figure 6: Broad Classification of Ovarian Cancer
Figure 7: Classification of Ovarian Cancer
Figure 8: Drug Model Diagram of Doxil
Figure 9: Doxil, Ovarian Cancer, Global, Sales Estimates ($m), 2002-2020
Figure 10: Doxil , Ovarian Cancer, The US, Sales Estimates ($m), 2002-2020
Figure 11: Doxil , Ovarian Cancer, The UK, Sales Estimates ($m), 2002-2020
Figure 12: Doxil , Ovarian Cancer, France, Sales Estimates ($m), 2002-2020
Figure 13: Doxil , Ovarian Cancer, Germany, Sales Estimates ($m), 2002-2020
Figure 14: Doxil , Ovarian Cancer, Italy, Sales Estimates ($m), 2002-2020
Figure 15: Doxil , Ovarian Cancer, Spain, Sales Estimates ($m), 2002-2020
Figure 16: Doxil , Ovarian Cancer, Japan, Sales Estimates ($m), 2009-2020
Figure 17: Doxil, Ovarian Cancer, Global, Sales Distribution (%), 2010
Figure 18: Patients Approved for the Drug Skip to top